ACM
ALDX icon

Altium Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Altium Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-864,020
Closed -$7.59M – 135
2021
Q3 		$7.59M Hold
864,020
– – 1.99% 5
2021
Q2 		$9.79M Buy
864,020
+315,795
+58% +$3.8M 2.27% 5
2021
Q1 		$6.51M Buy
+548,225
New +$6.31M 1.81% 6

Other funds holding ALDX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Altium Capital Management's ALDX Position: Q4 2021 in Review

Altium Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2021, closing a stake of 864,020 shares — an estimated $7.59M sold.

Altium Capital Management first reported a position in ALDX in Q1 2021 and held it in 3 quarters. The position peaked at $9.79M in Q2 2021. 115 funds tracked by Wall St. Rank hold ALDX as of Q4 2021.

  • Altium Capital Management reported no remaining Aldeyra Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Altium Capital Management sold 864,020 Aldeyra Therapeutics shares in Q4 2021, an estimated $7.59M.
  • Altium Capital Management first reported a position in Aldeyra Therapeutics in Q1 2021 and held it in 3 quarters.
  • Altium Capital Management's Aldeyra Therapeutics position peaked at $9.79M in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2021.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.